Work

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

Year: 2025

Type: article

Abstract: Eustachio Nettis has a conflict of interest with Sanofi, Abbvie, Leo Pharma, Almirall, Gsk, and Astra-Zeneca. The remaining authors have no conflicts of interest that are directly relevant to the content of this article. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Source: International Journal of Dermatology

DOI: 10.1111/ijd.70049

Authors: Mattia Cristallo, Ippolita Zaza, Michelina Francesca Daddato, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro, Sebastiano Gangemi, Eustachio Nettis

Institutions: University of Bari Aldo Moro, University of Messina

Language: English

Topic: melanin and skin pigmentation

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4413900873

FWCI: 0.863

Cites: 5

Cited by: 2

Related to: 10